Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2024 Financial Results Reports second quarter revenue of $154 million Second quarter orders of $157

Repligen Reports Second Quarter 2024 Financial Results

WALTHAM, Mass., July 30, 2024 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on

bioprocessing technology leadership, today reported financial results for its second quarter (Q2) of 2024, covering the three- and six- month periods ended June 30, 2024. Provided in this press release

are financial performance highlights, updates to our guidance for the full year 2024 and access information for today s webcast and conference call.

Tony J. Hunt, Chief Executive Officer of Repligen said, We delivered solid second quarter revenue of $154 million and first half revenue of

$305 million, achieving our year-to-date sales target. We are very encouraged by orders in the quarter, with continued strength in Pharma demand and a pickup in

CDMO activity. New modalities continued to show strong year-over-year momentum in both revenue and orders. Strategically, we strengthened our Proteins business with new product launches and our pending acquisition of Tantti Laboratory. We continue

to expect the second half of 2024 to outpace the first half on both revenue and orders. While we are narrowing our revenue guidance to reflect incremental China weakness, we are confident in Repligen s ability to resume above-industry growth in

the second half of 2024 and into 2025.

Q2 2024 BUSINESS HIGHLIGHTS

FINANCIAL PERFORMANCE

Q2 2024 FINANCIAL PERFORMANCE (compared to prior year, Q2 2023, except as noted)

All adjusted figures are non-GAAP and, except for earnings per share, are rounded to the nearest million.

Cash, cash equivalents and short-term investments at June 30, 2024, were $809 million, compared to $751 million

at December 31, 2023.

FINANCIAL GUIDANCE FOR FULL YEAR 2024

All Adjusted figures are non-GAAP

Our financial guidance for the full year 2024 is based on expectations for our existing business. Our GAAP and Adjusted guidance include the expected

impact of businesses acquired in 2023 (FlexBiosys and Metenova) and excludes the impact of any potential or pending business acquisitions in 2024, and future fluctuations in foreign currency exchange rates.

Conference Call and Webcast Access

Repligen will host a conference call and webcast today, July 30, 2024, at 8:30 a.m. ET, to discuss second quarter 2024 financial results, corporate

developments and financial guidance for 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers or (412) 317-5607 for

international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company s website. Both the conference call and webcast will be archived for a period

following the live event. The replay dial-in numbers are (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 6519285.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that

enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing

organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are in Waltham, Massachusetts, and the majority of our manufacturing sites are in the

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following Adjusted (non-GAAP) measures of financial performance are included in this release: book-to-bill ratios, organic revenue

growth, base business revenue growth, adjusted gross profit, adjusted gross margin and adjusted operating margin; adjusted cost of goods sold; adjusted R&D expense; adjusted SG&A expense; adjusted

pre-tax income; adjusted income from operations; adjusted net income; adjusted earnings per share-diluted; adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA

margin. The Company provides base revenue and base revenue growth rates, which exclude COVID-related revenue, and the impact of acquisition revenue for current year periods that have no prior year comparables, to facilitate a comparison of its

current revenue performance. The Company provides the impact of foreign currency translation, to enable determination of revenue growth rates at constant currency, which exclude the impact of foreign currency translation, in order to facilitate a

comparison of its current revenue performance to its past revenue performance. To calculate the impact of foreign currency translation, the Company converts actual net sales from local currency to U.S. dollars using constant foreign currency

exchange rates in the current and prior period.

The Company s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition and integration costs; restructuring charges including the costs of severance and accelerated depreciation among other charges; incremental costs attributed to

CEO transition; contingent consideration related to the Company s acquisitions; intangible amortization costs; non-cash interest expense related to the accretion of the debt discount; amortization of debt

issuance costs related to Company s convertible debt; foreign currency impact of certain intercompany loans; and, the related impact on tax of non-GAAP charges. These costs are excluded because management

believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

All reconciliations of above GAAP figures

(reported or guidance) to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. When analyzing the Company s operating performance and guidance, investors should not

consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

Forward-Looking Statement

This release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws,

including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in the release do not

constitute guarantees of future performance. Investors are cautioned that statements in this release which are not strictly historical statements, including, among others; any express or implied statements or guidance regarding current or future

financial performance and position, including our updated 2024 financial guidance and related assumptions; expected demand in the markets in which we operate (including the belief that such markets will improve and the impact of such improvement on

our business); the expected performance of our business; the expected performance and success of our strategic partnerships and integration of our acquired businesses, constitute forward-looking statements identified by words like

believe, expect, may, will, should, seek, anticipate, projected, estimated or could and similar expressions. Forward-looking

statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are subject to a number of risks and uncertainties that could cause actual results to differ materially from

those anticipated, including, our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds, including to achieve our updated 2024 financial guidance; our ability to develop and commercialize

products and the market acceptance of our products; our ability to successfully integrate any acquired businesses (including Metenova and FlexBiosys) into our business, or to close potential or pending acquisitions (including Tantti) in a timely

manner or at all, and achieve the expected benefits of such acquisitions; that the impact from our recently announced cyber incident may be more impactful than anticipated; that demand for our products could continue to decline, which could

adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all U.S. Food and

Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; and other risks detailed in Repligen s filings with the U.S. Securities and Exchange Commission (the Commission), including Annual Report on

Form 10-K for the year ended December 31, 2023 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and current

reports on Form 8-K. Actual results may differ materially from those Repligen contemplated by these forward-looking statements; therefore, you should not rely on any of these forward-looking statements. These

forward-looking statements reflect management s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions,

and are based only on information currently available to us. Repligen does not undertake to update, whether written or oral, any of these forward-looking statements to reflect a change in its views or events or circumstances, whether as a result of

new information, future development or otherwise, that occur after the date hereof except as required by law.

Global Head of Investor Relations

REPLIGEN CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, amounts in thousands, except share and per share data)

REPLIGEN CORPORATION

RECONCILIATIONS OF GAAP to NON-GAAP FINANCIAL MEASURES

(Unaudited, amounts in thousands, except percentage and earnings per share data)

In all tables below, totals may not add due to rounding

Reconciliation of Reported Revenue (GAAP) Growth to Organic Revenue Growth (Non-GAAP)

Reconciliation of Total Revenue (GAAP) to Base Revenue (Non-GAAP)

Reconciliation of Income from Operations (GAAP) to Adjusted Income from Operations (Non-GAAP)

Reconciliation of Net Income (GAAP) to Adjusted Net Income (Non-GAAP)

Reconciliation of Earnings Per Share (GAAP) to Adjusted Earnings Per Share

Reconciliation of Net Income (GAAP) to Adjusted EBITDA (Non-GAAP)

Reconciliation of Cost of Goods Sold (GAAP) to Adjusted Cost Goods Sold

Reconciliation of R&D Expense (GAAP) to Adjusted R&D Expense (Non-GAAP)

Reconciliation of SG&A Expense (GAAP) to Adjusted SG&A Expense (Non-GAAP)

Reconciliation of Net Income (GAAP) Guidance to Adjusted Net Income

Reconciliation of Earnings Per Share (GAAP) Guidance to Adjusted Earnings Per Share

FOOTNOTES FOR ALL TABLES ABOVE (amounts in thousands):

for benefit received on the sale of